Frontiers of Digital Transformation
in Drug R&D
The COVID-19 pandemic has made us realize that everyone is vulnerable. Throughout this period of unparalleled disruption, one of the most important sectors – healthcare – has been at the forefront of unimaginable change. We’ve seen how the safe and responsible use of data about people has been fundamental to driving greater advancements in patient health.
Watch our keynote presentation recorded July 22, 2021, at the virtual MIT CDOIQ Symposium and get key insights to help you build trusted data strategies for innovation that benefits everyone.
Situation: California’s Consumer Privacy Act inspired Comcast to evolve the way in which they protect the privacy of customers who consent to share personal information with them.
Situation: Integrate.ai’s AI-powered tech helps clients improve their online experience by sharing signals about website visitor intent. They wanted to ensure privacy remained fully protected within the machine learning / AI context that produces these signals.
Situation: Novartis’ digital transformation in drug R&D drives their need to maximize value from vast stores of clinical study data for critical internal research enabled by their data42 platform.
Situation: CancerLinQ™, a subsidiary of American Society of Clinical Oncology, is a rapid learning healthcare system that helps oncologists aggregate and analyze data on cancer patients to improve care. To achieve this goal, they must de-identify patient data provided by subscribing practices across the U.S.
Situation: Needed to enable AI-driven product innovation with a defensible governance program for the safe and responsible use
of voice-to-text data under Shrems II.
This course runs on the 2nd Wednesday of every month, at 11 a.m. ET (45 mins). Click the button to register and select the date that works best for you.